Mounjaro (tirzepatide) is a prescription drug used to help manage blood sugar levels in adults with type 2 diabetes. Mounjaro comes as an injection that’s given under your skin. This medication ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

Inc. (NYSE American: PTN), a small-cap biotech company with a market capitalization of $20.4 million, has announced its corporate milestones for 2025, focusing on the development of treatments for ...

Shortly after the OFA filed its lawsuit, the FDA said it would review its decision to remove Lilly’s tirzepatide products from its shortage list—though the agency ultimately stuck by its ...

According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and weight-loss tirzepatide injection products (Mounjaro and ...

The FDA announced that the tirzepatide injection shortage is resolved. Hims & Hers Health, Inc.'s stock fell 6.90%, reflecting market concerns over regulatory updates and supply chain stability.

Weight-loss injection Mounjaro, also known as tirzepatide, will be rolled out on the NHS gradually over a 12-year period, starting this year, but many eligible patients will have to wait.

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...